SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-007069
Filing Date
2024-05-07
Accepted
2024-05-07 16:30:43
Documents
65
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q acrs-20240331x10q.htm   iXBRL 10-Q 1404720
2 EX-31.1 acrs-20240331xex31d1.htm EX-31.1 15615
3 EX-31.2 acrs-20240331xex31d2.htm EX-31.2 15656
4 EX-32.1 acrs-20240331xex32d1.htm EX-32.1 9518
  Complete submission text file 0001558370-24-007069.txt   6611228

Data Files

Seq Description Document Type Size
5 EX-101.SCH acrs-20240331.xsd EX-101.SCH 36678
6 EX-101.CAL acrs-20240331_cal.xml EX-101.CAL 39688
7 EX-101.DEF acrs-20240331_def.xml EX-101.DEF 160928
8 EX-101.LAB acrs-20240331_lab.xml EX-101.LAB 391949
9 EX-101.PRE acrs-20240331_pre.xml EX-101.PRE 270569
69 EXTRACTED XBRL INSTANCE DOCUMENT acrs-20240331x10q_htm.xml XML 1301095
Mailing Address 701 LEE ROAD SUITE 103 WAYNE PA 19087
Business Address 701 LEE ROAD SUITE 103 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

IRS No.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37581 | Film No.: 24922499
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)